Cellectar Biosciences Inc (CLRB) concluded trading on Wednesday at a closing price of $0.46, with 620.73 million shares of worth about $285.53 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -70.02% during that period and on June 04, 2025 the price saw a gain of about 66.32%. Currently the company’s common shares owned by public are about 46.08M shares, out of which, 45.31M shares are available for trading.
Stock saw a price change of 87.84% in past 5 days and over the past one month there was a price change of 73.51%. Year-to-date (YTD), CLRB shares are showing a performance of 54.41% which decreased to -85.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $3.42 during that period. The average intraday trading volume for Cellectar Biosciences Inc shares is 972.43K. The stock is currently trading 75.04% above its 20-day simple moving average (SMA20), while that difference is up 64.28% for SMA50 and it goes to -52.40% lower than SMA200.
Cellectar Biosciences Inc (NASDAQ: CLRB) currently have 46.08M outstanding shares and institutions hold larger chunk of about 11.42% of that.
The stock has a current market capitalization of $21.27M and its 3Y-monthly beta is at 0.52. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 2.47 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLRB, volatility over the week remained 24.90% while standing at 12.02% over the month.
Stock’s fiscal year EPS is expected to rise by 53.01% while it is estimated to decrease by -9.88% in next year. EPS is likely to shrink at an annualized rate of 19.07% for next 5-years, compared to annual growth of 40.27% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on December 05, 2024 offering a Buy rating for the stock and assigned a target price of $13 to it. Stock get a Buy rating from Ladenburg Thalmann on December 21, 2016.
